Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, comments on the role of chemotherapy in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), highlighting data from a Phase II study comparing the outcomes of patients with BPDCN who received frontline hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate/ARA-C (HCVAD)-based vs non-HCVAD based treatment regimens (NCT04216524). The study highlighted the important role of HCVAD-based chemotherapy in these patients, even in the context of targeted therapies including CD123-targeting agents. Dr Pemmaraju also comments on the need for combination approaches with chemotherapy, targeted therapies and central nervous system (CNS)-directed therapies and argues that such strategies could lead to the long-term eradication of BPDCN. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.